LALPATHLAB / NSE / Healthcare Facilities

Dr. Lal PathLabs

INR 1,539.3-62.20 (-1.20%) 1D

Last updated: 2026-06-16T04:38:17.209472+00:00

Price Chart

1Y Price Trend

Open1,476.7

High1,770

Low1,272.6

Close1,616

Volume2,17,507

Change139.3

Change %9.43%

Key Information

Ticker SymbolLALPATHLAB

Current Price1,539.3

52-Week High1,770

52-Week Low1,272.6

Market Cap25,871.05

Beta0.87

Volume2,17,507

ISININE600L01024

Day High1,628.1

Day Low1,579.2

Open1,625.7

Recommendations

RatingBuy

Target High1,771.3

Target Low1,272

Target Mean1.92

Target Median15

Risk Metrics

Overall RiskBalanced risk

Board Risk31.84

Key Analysis

Overall score, performance score, return rating, defensive, aggressive, and balanced views.

Download app

Projection Analytics

Best-case, base-case, worst-case, and dynamic AI projection views.

Download app

News

Latest stock news

Dr Lal Pathlabs Ltd is Rated Hold by MarketsMOJO - Markets Mojo13 days ago

Market news

Dr Lal Pathlabs Ltd is Rated Hold by MarketsMOJO Markets Mojo

Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - Markets Mojo14 days ago

Market news

Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Indicator Signals Markets Mojo

Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets Mojo15 days ago

Market news

Dr Lal Pathlabs Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo

Dr. Lal PathLabs Schedules Analyst and Institutional Investor Meeting on May 20, 2026 - scanx.trade28 days ago

Market news

Dr. Lal PathLabs Schedules Analyst and Institutional Investor Meeting on May 20, 2026 scanx.trade

Dr. Lal PathLabs FY26 Audited Results: Revenue Up 12.2%, Dubai Subsidiary Approved - scanx.trade1 month ago

Market news

Dr. Lal PathLabs FY26 Audited Results: Revenue Up 12.2%, Dubai Subsidiary Approved scanx.trade

Dr Lal PathLab Standalone March 2026 Net Sales at Rs 675.20 crore, up 16.98% Y-o-Y - Moneycontrol.com1 month ago

Market news

Dr Lal PathLab Standalone March 2026 Net Sales at Rs 675.20 crore, up 16.98% Y-o-Y Moneycontrol.com

Dr. Lal Pathlabs among 5 stocks showing bullish RSI upswing - The Economic Times1 month ago

Market news

Dr. Lal Pathlabs among 5 stocks showing bullish RSI upswing The Economic Times

Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive - Business Standard1 month ago

Market news

Dr Lal PathLabs hits 20% upper band on strong Q4; brokerages stay positive Business Standard